Market Overview

Global In-Vitro Diagnostics (IVD) Market, 2013-2018 & 2022 - Market Size is Expected to Reach USD 97.01 Billion


Global In-Vitro Diagnostics (IVD) Market, 2013-2018 & 2022 - Market Size is Expected to Reach USD 97.01 Billion

PR Newswire

DUBLIN, Aug 24, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "In Vitro Diagnostics (IVD) Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Clinical Chemistry, Molecular Diagnostics, Coagulation, Microbiology), By End User, And Segment Forecasts, 2013 - 2022" report has been added to's offering.

The global in vitro diagnostics (IVD) market size is expected to reach USD 97.01 billion by 2022, rising at a CAGR of 6.8% during the forecast period.

Increasing incidence of sexually transmitted and gastrointestinal diseases coupled with surging demand for large-scale screening, particularly for cancer, is stimulating the growth of the market. IVD helps in detecting whether a particular medicine or treatment would work on a patient.

Constant innovations and advancements play a pivotal role in the development of the market. IVD is being increasingly used in every stage of the patient care and nearly each healthcare setting. Though, most of these tests are remotely performed, making their presence unnoticed.

Various organizations are functioning to monitor the market. For instance, BIVDA is an association of companies with high involvement and interest and represents manufacturers and distributors functioning in the U.K.

Rapidly changing healthcare environment and growing acknowledgment of diagnostics role in patient care, along with rising awareness regarding importance of early diagnosis of chronic diseases, are likely to boost the growth of the IVD market.

Surging demand for point-of-care detection and identification of various infectious diseases such respiratory tract infections, including Legionnaires' disease, RSV, influenza, and pneumonia, coupled with pathogens causing filariasis and malaria, is providing a significant push to the market.

Further key findings from the report suggest:

  • Reagents were the largest segment in 2016 and are expected to show the fastest growth over the forecast period owing to rising R&D activities pertaining to self-test and point-of-care products
  • Infectious disease dominated the market in 2016 due to increasing incidence of infectious diseases such as pneumonia, tuberculosis, and HIV.
  • Hospitals were one of the largest segment in 2016 owing to rising number of hospitalized patients
  • North America dominated the IVD market in 2016 due to rising prevalence of chronic disorders such as respiratory diseases and cancer in this region
  • Asia Pacific is expected to be the fastest growing region over the forecast period. Rising per capita healthcare expenditure, government initiatives, and growing clinical research activities for advanced diagnostics are likely to drive the regional market.

Key Topics Covered:

Chapter 1. Executive Summary
1.1. IVD - Industry Summary and Critical Success Factors (CSFs)

Chapter 2. IVD Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. IVD Market Dynamics
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Molecular Diagnostics - Company Market Share Analysis
2.7. Tissue Diagnostics - Company Market Share Analysis
2.8. Professional Diagnostics - Company Market Share Analysis
2.9. Diabetes Monitoring - Company Market Share Analysis
2.10. IVD Market PESTEL Analysis, 2012

Chapter 3. IVD Product Outlook
3.1. Molecular Diagnostics
3.2. Tissue Diagnostics
3.3. Diabetes Monitoring
3.4. Professional Diagnostics

Chapter 4. IVD Regional Outlook

Chapter 5. Competitive Landscape

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthcare
  • Johnson and Johnson
  • Bio-Rad Laboratories
  • Beckman Coulter Inc.
  • Becton Dickinson
  • bioMerieux
  • Sysmex
  • Bayer Healthcare
  • Alere Inc.
  • Danaher Corporation
  • Hologic (Gen-Probe)
  • Novartis
  • Cepheid
  • Qiagen
  • Leica Biosystems
  • Dako

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content with multimedia:

SOURCE Research and Markets

View Comments and Join the Discussion!